Details of the Drug

General Information of Drug (ID: DMXJ8Z4)

Drug Name
AK104
Indication
Disease Entry ICD 11 Status REF
Cervical cancer 2C77.0 Phase 2 [1]
Hepatocellular carcinoma 2C12.02 Phase 2 [2]
Drug Type
Antibody
Cross-matching ID
TTD ID
DXJH93
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4) TTI2S1D CTLA4_HUMAN Inhibitor [3]
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Cervical cancer
ICD Disease Classification 2C77.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cytotoxic T-lymphocyte protein 4 (CTLA-4) DTT CTLA4 2.73E-01 0.02 0.05
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04380805) A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04728321) A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of Akeso Biopharma.